Skip to main content
C

Celestra Inc. — Investor Relations & Filings

Ticker · 352770 ISIN · KR7352770002 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2024-03-18 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 352770

About Celestra Inc.

https://celestrahealth.com/

Celestra Inc. develops and commercializes digital biomarkers for monitoring neurological conditions. The company's core product is the Celestra Health platform, an FDA-designated Class II medical device that provides quantitative gait analysis for patients in their natural environment. The platform utilizes wearable smart insoles equipped with gyroscopes, accelerometers, and pressure sensors to collect movement data. This data is processed by a cloud-based system using advanced machine learning algorithms to measure over 200 aspects of a patient's gait. The system is designed to detect subtle changes in disease progression for conditions such as Multiple Sclerosis and Parkinson’s Disease earlier than traditional clinical assessments. It offers laboratory-grade accuracy, providing clinicians with actionable insights through a proprietary composite index and enabling pharmaceutical firms to assess drug therapy effectiveness more efficiently.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a decision on a paid-in capital increase (유상증자결정) for Clinomics Co., Ltd. It details the amendment of payment dates, allocation of shares to third parties, and changes in the largest shareholder. This type of filing is a formal regulatory disclosure concerning capital structure changes and share issuance, which falls under the 'Share Issue/Capital Change' category.
2024-03-18 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Clinomics. It contains the meeting agenda, details on voting procedures (including electronic voting), and management information such as director nominations and board activity reports. This document is a standard proxy statement/notice of meeting sent to shareholders to inform them of the upcoming AGM and solicit their votes.
2024-03-15 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation Statement). It contains information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, details on proxy solicitation, and financial statements for the fiscal year. While it contains financial data, its primary purpose is to solicit proxies for the AGM, making it a Proxy Solicitation & Information Statement.
2024-03-15 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Clinomics. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and business purpose changes) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and the matters to be voted upon.
2024-03-14 Korean
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal notification filed by Clinomics regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date where many companies hold their AGMs). It explains the reasons for choosing this date despite regulatory efforts to encourage dispersion. This is a regulatory disclosure related to corporate governance and meeting logistics, which falls under the general regulatory filing category as it does not contain the actual proxy materials or voting results.
2024-03-14 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) filed with the Korea Exchange. It details the correction of payment dates and share issuance schedules. This type of filing, which concerns changes to capital structure and share issuance, falls under the 'Share Issue/Capital Change' category.
2024-03-13 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.